Skip to content

Study · Not a test of the peptide alone · 2024

4 results

Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.

Nigam A

The Journal of the Association of Physicians of India1 Sept 2024Cited by 2 (Europe PMC)

PMID39291515 (opens in a new tab)DOI10.59556/japi.72.0644 (opens in a new tab)PepBankPUB-39291515
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In overweight or obese Indian diabetes patients, dulaglutide plus canagliflozin use was linked to a -1.3% A1c change at week 32.

    In plain wordsIn Indian diabetes patients, dulaglutide plus canagliflozin use was linked to lower A1c than baseline at week 32.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at week 32 in RWE 1
    Study

    n = 40

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.3%
    RWE 1, week 32
    HbA1c baseline
    8.4%
    RWE 1
    HbA1c at week 32
    7.1%
    RWE 1

    Source sentences

    Summary
    At week 32, the mean (SD) reduction in A1c (%) was -1.3% [8.4 (0.7) to 7.1 (0.3); p p < 0.00001].
    2 context sentences
    Summary · context
    In two real-world evidence (RWE) studies (RWE1 and 2), we retrospectively observed the effect of the combination therapy of a GLP-1RA, injection dulaglutide (DU) 1.5 mg/week, and an SGLT-2i, canagliflozin (CAN) 100 mg/day
    Summary · context
    In RWE 1, 40 patients (20 M/20 F), mean [standard deviation (SD)] age 49.4 (10.7) years (Y), weight 92.6 (6.6) kg, body mass index (BMI) 30.6 (2.3) kg/m2, duration of T2D 8.1 (3.2) Y, completed the study.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In overweight or obese Indian diabetes patients, dulaglutide plus canagliflozin use was linked to lower weight than baseline at week 32.

    In plain wordsIn Indian diabetes patients, dulaglutide plus canagliflozin use was linked to lower weight than baseline at week 32.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight at week 32 in RWE 1
    Study

    n = 40

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Body weight change
    −5.5 kg
    RWE 1, week 32
    Body weight baseline
    92.6 kg
    RWE 1
    Body weight at week 32
    87.9 kg
    RWE 1

    Source sentences

    Summary
    At week 32, the mean (SD) reduction in A1c (%) was -1.3% [8.4 (0.7) to 7.1 (0.3); p p < 0.00001].
    2 context sentences
    Summary · context
    In two real-world evidence (RWE) studies (RWE1 and 2), we retrospectively observed the effect of the combination therapy of a GLP-1RA, injection dulaglutide (DU) 1.5 mg/week, and an SGLT-2i, canagliflozin (CAN) 100 mg/day
    Summary · context
    In RWE 1, 40 patients (20 M/20 F), mean [standard deviation (SD)] age 49.4 (10.7) years (Y), weight 92.6 (6.6) kg, body mass index (BMI) 30.6 (2.3) kg/m2, duration of T2D 8.1 (3.2) Y, completed the study.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In RWE 2, A1c decreased by 1.4% from baseline in 71% of subjects receiving dulaglutide plus canagliflozin at week 16.

    In plain wordsIn Indian patients with diabetes, A1c decreased from baseline in 71% receiving dulaglutide plus canagliflozin at week 16.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at week 16 in RWE 2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Proportion of subjects with A1c decrease
    71%
    RWE 2, week 16
    HbA1c change
    −1.4%
    RWE 2, week 16
    HbA1c baseline
    8.5%
    RWE 2
    HbA1c at week 16
    7.1%
    RWE 2

    Source sentences

    Summary
    In 71% of subjects, A1c decreased by -1.4% [8.5 ± 0.4 to 7.1 ± 0.2; p p = 0.0002) in 18% at week 32.
    2 context sentences
    Summary · context
    In two real-world evidence (RWE) studies (RWE1 and 2), we retrospectively observed the effect of the combination therapy of a GLP-1RA, injection dulaglutide (DU) 1.5 mg/week, and an SGLT-2i, canagliflozin (CAN) 100 mg/day
    Summary · context
    In RWE 2, 55 patients (31 M/24 F), age 51 (5.8) Y, weight 92.6 ± 3.4 kg, BMI 31.1 ± 2.1 kg/m2, SBP 142.4 ± 3.9 mm Hg, estimated glomerular filtration rate (eGFR) 62 ± 5 mL/minute/1.73 m2, with 8.4 ± 3.3 Y duration of diabetes met the inclusion criteria.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In RWE 2, A1c was 6.8 ± 0.3 in 18% of subjects receiving dulaglutide plus canagliflozin at week 32.

    In plain wordsIn Indian patients with diabetes, A1c was 6.8 in 18% receiving dulaglutide plus canagliflozin at week 32.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at week 32 in RWE 2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c at week 32
    6.8%
    RWE 2, subset
    Proportion of subjects
    18%
    RWE 2, week 32

    Source sentences

    Summary
    In 71% of subjects, A1c decreased by -1.4% [8.5 ± 0.4 to 7.1 ± 0.2; p p = 0.0002) in 18% at week 32.
    2 context sentences
    Summary · context
    In two real-world evidence (RWE) studies (RWE1 and 2), we retrospectively observed the effect of the combination therapy of a GLP-1RA, injection dulaglutide (DU) 1.5 mg/week, and an SGLT-2i, canagliflozin (CAN) 100 mg/day
    Summary · context
    In RWE 2, 55 patients (31 M/24 F), age 51 (5.8) Y, weight 92.6 ± 3.4 kg, BMI 31.1 ± 2.1 kg/m2, SBP 142.4 ± 3.9 mm Hg, estimated glomerular filtration rate (eGFR) 62 ± 5 mL/minute/1.73 m2, with 8.4 ± 3.3 Y duration of diabetes met the inclusion criteria.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.